Most material SEC filings — October 26, 2026

The NYSE delisted Elme Communities' common shares effective October 23, 2026, due to abnormally low selling price. Trading suspended immediately; shares will trade OTC under symbol ELMES beginning October 26, 2026. The delisting follows Elme's previously approved Plan of Sale and Liquidation; the company intends to dissolve November 6, 2026, transferring remaining assets to a liquidating trust managed by FTI Consulting, with shareholders receiving non-tradable beneficial interests.

Amanat Acquisition Corp (SPAC, ~$77M assets) has signed a definitive Business Combination Agreement dated October 25, 2026, to merge with Corxel Pharmaceuticals Limited and Corxel Pharmaceuticals, Inc. The transaction values Corxel at an Equity Value of $200,000,000. SPAC will issue Aggregate Transaction Share Consideration to Corxel shareholders at an Exchange Ratio derived from dividing $200M by the SPAC Share Value. The deal includes a PIPE financing component and requires SPAC shareholder approval and regulatory filings (HSR Act, SEC, Nasdaq). At closing, SPAC will domesticate from Cayman Islands to Delaware, then merge with Corxel in a two-step process.

EQT Corporation agreed to acquire Range Resources Corporation in an all-stock merger whereby each Range Resources common share converts into 0.987 EQT shares (Exchange Ratio). The transaction involves a two-step merger structure with Range Resources becoming an indirect wholly owned subsidiary of EQT. Range shareholders receive EQT shares as sole consideration; Range equity awards are assumed and converted at the same ratio. Two Range designees (Dennis L. Degner and one other) join EQT's 12-person board. No deal value or financing terms are specified in this merger agreement excerpt.

EQT Corporation agreed to acquire Range Resources Corporation in a two-step merger dated October 25, 2026. Range Resources shareholders will receive 0.987 EQT shares per Range share (Exchange Ratio). As of the measurement date (October 23, 2026), Range had 233.7M common shares outstanding plus 3.5M shares subject to equity awards. Range's boards unanimously approved; deal includes board representation (2 directors) for Range designees post-closing.

GameSquare completed acquisition of FanEngine Holdings Ltd.'s sports, music, and entertainment IP assets on October 22, 2026, following stockholder approval. The transaction adds globally recognized franchises including Peaky Blinders, Simon's Cat, and 15 global athletes. GameSquare projects 2027 revenue exceeding $150M, gross margin above 50%, and adjusted EBITDA above $30M; FanEngine expected immediately accretive to adjusted EBITDA in Q4 2026.

Game Your Game amended two warrants issued to Streeterville Capital, LLC (dated March 31 and June 30, 2026) effective October 23, 2026, reducing exercise prices to $1.00 per share for both debt and preferred warrants. Separately, the company hired Wendy Loundermon as CFO at $200k base salary plus $25k signing bonus and 200k stock options (4-year vest). CEO Soumya Das received a first amendment raising base salary to $300k (from unspecified prior amount, effective October 1, 2026) and establishing $200k annual bonus tied to performance milestones, plus acquisition bonuses (3-1% tiered on transaction value). The filing does not disclose original warrant exercise prices, number of warrant shares, or prior CEO compensation.

Climb Bio announced initial Phase 2 PrisMN data for budoprutug (anti-CD19 mAb) in primary membranous nephropathy at ASN Kidney Week 2026 (Oct 24). The 200 mg low-dose cohort demonstrated 70% mean PLA2R antibody reduction and 38% immunologic remission rate (71% in high-baseline-PLA2R subgroup) at Week 12, with 98% B-cell depletion at Week 4 in the 600 mg cohort. Budoprutug was generally well-tolerated; no serious adverse events, discontinuations, or deaths reported. Additional data from all dose cohorts expected in 2027.

Soluna repaid $28.7M in principal to Generate Capital ($19.1M in August 2026, remainder in October 2026), fully retiring the credit facility and releasing liens on Dorothy 3 AI campus assets. Total company debt principal decreased from $37.9M (June 30, 2026) to $9.2M, a 76% reduction. The Generate facility, entered September 2025, had financed Dorothy 1A/2 refinancing, Dorothy 2 completion, and the April 2026 acquisition of the 150 MW Briscoe Wind Farm.

Valion Bio announced it received unsolicited acquisition inquiries from independent third parties regarding its wholly owned CDMO subsidiary Velocity Bioworks. The company has engaged a financial advisor and entered preliminary discussions while evaluating strategic options, with a key priority of retaining manufacturing rights for its lead candidate Entolimod. No specific dollar amounts, valuation, or transaction terms were disclosed, and discussions remain preliminary with no commitment to a sale.

Oruka announced positive Week 16 interim results from EVERLAST-B, a 187-patient Phase 2b trial of ORKA-001 (IL-23p19 monoclonal antibody) in moderate-to-severe psoriasis. The high-dose group (600 mg at Weeks 0 and 4) achieved 61% PASI 100 and 86% PASI 90 versus 0% placebo (p<0.0001), with safety comparable to placebo (39% vs 43% any adverse events). Company plans Phase 3 initiation in 1H 2027 and reports >$1B cash runway through BLA filing.

Medifast reported Q3 2026 revenue of $72.0M (down 19.4% YoY from $89.4M) driven by active earning coaches declining 47.7% to 10,200 from 19,500. Net loss was $17.5M ($1.57/share) including $15.4M in Catalyst restructuring charges; non-GAAP adjusted net loss was $2.1M ($0.19/share). Company maintains $172.5M cash with no debt. Q4 2026 revenue guidance: $55M–$75M; full-year 2026 revenue guidance narrowed to $280M–$300M (previously wider range).

Braemar's Board nominated eight directors for the 2026 Annual Meeting, including seven new independent nominees and CEO Richard Stockton. The slate follows termination of Braemar's external advisory relationship with Ashford Inc. and its affiliates; all incumbent directors tied to Ashford are stepping aside. Once seated, the new Board will select an independent Chairman. Ferguson Partners conducted the executive search.

Ovintiv Inc. (via subsidiary Ovintiv Canada ULC) agreed on October 26, 2026 to acquire all issued and outstanding common shares of Logan Energy Corp. for $1.40 per share in cash, plus Logan shareholders receive shares and warrants in newly-listed Newco (valued at $1.00/share, minimum $100M financing). The transaction is structured as a court-approved arrangement under Alberta law, with Logan shareholders also receiving Newco equity (initially held by Logan and distributed). Closing targeted for early 2027, subject to court approval, Competition Act clearance, and shareholder votes.

Acumen Pharmaceuticals, a $45.3M market-cap clinical-stage biotech, reported cash of $78.6M as of September 30, 2026 (down from $110.2M on June 30, 2026). The company expects to report topline results from ALTITUDE-AD, a 542-participant Phase 2 trial of sabirnetug (ACU193) for early Alzheimer's disease, in November 2026. Q3 2026 R&D expenses were $21.1M vs. $22.0M year-over-year; net loss was $25.4M vs. $26.5M. Cash is projected to support operations into early 2027. An IND filing for the Enhanced Brain Delivery program lead candidate is targeted for mid-2027.

Xencor presented Phase 1 data for XmAb819 (ENPP3 x CD3 bispecific) in advanced clear cell renal cell carcinoma (ccRCC) as of September 1, 2026. Across 68 expansion-dose patients (100, 200, 400 mcg/kg), confirmed objective response rates were 30%, 44%, and 45.5% respectively; 400 mcg/kg achieved 82% 6-month PFS Kaplan-Meier estimate. Company selected 400 mcg/kg IV as proposed Phase 3 dose and plans to discuss accelerated approval pathway with FDA in 1H2027, with registration-enabling study initiation targeted by end of 2027. Global randomized trial versus tivozanib control is planned for post-PD-(L)1 and VEGFR-TKI patients.

Eikon presented updated Phase 2 data from TeLuRide-005 (n=72 participants) showing EIK1001 combined with pembrolizumab and chemotherapy achieved 72% objective response rate and 100% disease control rate in the squamous NSCLC cohort with 12.7 months median follow-up and 12.9 months median duration of response. The combination was well-tolerated with 48.6% Grade 3+ treatment-related adverse events and 6.9% discontinuation rate. TeLuRide-008, a Phase 2/3 registrational trial, is actively enrolling with interim analysis for dose selection expected in H2 2027.

ArriVent announced initial Phase 1 data for ARR-217 (CDH17-targeted ADC) from a 123-patient study (113 CRC patients) as of August 5, 2026. At the 6 mg/kg dose, 44.8% ORR (13/29 patients) was observed in heavily pretreated CRC patients with 93.1% disease control rate; safety profile was manageable with 20.4% Grade 3+ adverse events at the 6 mg/kg dose and no Grade 5 events. ARR-217 advances to Phase 1b dose optimization with data expected in 2027.

Alliance Resource Partners completed a $206.2 million acquisition of AllDale Minerals III and IV on July 1, 2026, adding ~48,500 net royalty acres across premier basins. Q3 2026 net income attributable to ARLP surged 46.8% YoY to $139.6M on revenues of $603.0M (up 5.5% YoY); Adjusted EBITDA attributable to ARLP increased 26.3% YoY to $233.9M. Coal segment Adjusted EBITDA was $186.8M (up 23.1% sequentially); Oil Gas Royalties segment contributed a record $43.6M (up 61.4% YoY). Board declared quarterly cash distribution of $0.60/unit ($2.40 annualized) with Distribution Coverage Ratio of 1.76x.

MainStreet Bancshares reported Q3 2026 net income of $3.6 million ($0.43 EPS) on net interest income of $18.8 million. The company added a $1.9 million provision for credit losses ($0.21 EPS impact) due to commercial real estate stress. Non-performing assets surged to 4.20% of total assets (from 1.10% YoY), and non-accrual loans jumped to 4.71% of gross loans (from 1.29% YoY), signaling material deterioration in credit quality.